“Why do I do what I do? It’s simple… for the patients. Their smiles, their stories, and the success that they have is what gets me up in the morning. I love what I do, and with each patient that we hear from, that drive to keep going gets stronger.”
Justin Gover is GW’s chief executive officer and a member of its board of directors. He joined as CEO in January 1999, shortly after the company was founded. In 2015, he relocated from the UK to open the company’s U.S. headquarters in California.
Prior to GW, Justin was head of corporate affairs at Ethical Holdings PLC, a UK-based publicly traded biopharmaceutical company now known as Amarin Corporation, where he led corporate strategy, mergers, acquisitions, strategic investments, equity financing and investor relations.
Justin earned a Bachelor of Science from the University of Bristol, Bristol, UK, and his MBA from INSEAD Business School, Fontainebleau, France. He serves on the board of directors of the Biotechnology Innovation Organization.
“There’s nothing quite like knowing that the work we do is making a difference for patients and their families.”
Darren Cline is GW’s U.S. chief commercial officer, a role he has held since joining the company in April 2019. He has over 25 years of commercial experience, particularly in rare disease.
As U.S. commercial leader, Darren is responsible for product sales, marketing, market access and account management, plus medical affairs, patient advocacy and scientific communication.
Prior to GW, Darren was executive vice president of commercial and a member of the executive committee at Seagen, where he oversaw all marketing, sales and managed markets functions, and contributed to the U.S. commercial launch of Adcetris for Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Previously, he led U.S. sales at Alexion Pharmaceuticals, where he built sales functions to launch Soliris, a first-in-class terminal complement inhibitor, and help it become a billion-dollar brand. Darren also held commercial and marketing leadership roles at Intermune and Amgen. He started his career in pharmaceutical sales at Schering-Plough.
Darren earned a bachelor’s degree from San Diego State University, San Diego, California, and his MBA from Pepperdine University, Malibu, California.
“We don’t simply say we put patients first, we live it. That’s what fuels me.”
Scott Giacobello is GW’s chief financial officer, a role he has held since joining the company in March 2017. He has more than 25 years of finance and operational experience.
As CFO, Scott is responsible for the company’s finance, accounting, tax, treasury, corporate strategy and business development activities.
Prior to GW, Scott served as chief financial officer for Chase Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders, until its acquisition by Allergan in late 2016. From 2008-2015, he held senior level finance positions at Allergan, including vice president of finance for global research and development, vice president of corporate finance and vice president of internal audit and compliance. He also held finance roles at Black & Decker and Ernst & Young.
Scott holds a bachelor’s degree in business administration from the University of Notre Dame, Notre Dame, Indiana, and is a certified public accountant (CPA).
“Scientific rigor is something we pride ourselves in. We bring science to cannabinoid medicines, but more than that, we bring humanity too it—we put our patients first.”
Dr. Volker Knappertz is GW’s chief medical officer, a role he has held since joining the company in 2017. He has over 20 years of pharmaceutical drug development and leadership experience, including management of global drug development programs as well as global medical affairs.
As CMO, Volker is responsible for the company’s research and development efforts, as well as life-cycle management of our approved medicines.
Prior to GW, Volker served as vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva Pharmaceuticals. He previously served in clinical development roles in central nervous system, cardiovascular therapeutics and biologics at both Bayer Pharmaceuticals and AstraZeneca.
Volker is a U.S. board certified neurologist with residency training at Yale University School of Medicine, New Haven, Connecticut, where he served as chief resident, and fellowship training at Wake Forest University School of Medicine, Winston-Salem, North Carolina. He received his clinical scientist training and Doctor of Medicine from the University at Cologne, Koln, Germany. Volker has also maintained an adjunct faculty position with the department of neurology at the Heinrich-Heine University, Dusseldorf, Germany, since 2010. He has contributed to scientific and clinical research through multiple publications during his career and has served on several industry regulatory and scientific committees pertaining to his drug development work.
“Our patients come first. That’s our motto, and it drives every action, every decision, every employee—that’s what makes GW Pharmaceuticals truly unique.”
Doug Snyder is GW’s chief legal officer, a role he has held since joining the company in July 2017. He has been providing counsel in the pharmaceutical industry and public sector for over 25 years.
As CLO, Doug is responsible for corporate and business legal counsel, intellectual property, public policy, government affairs and compliance. He also serves as GW’s company secretary.
Prior to GW, Doug was senior vice president, general counsel and secretary with responsibility for legal and compliance functions at Actelion Pharmaceuticals US, now a Janssen company. He previously served as senior vice president, general counsel and secretary at Eisai US, a human health care company, where he led legal, compliance, legislative affairs, internal audit and security. Doug was also vice president and associate general counsel for GlaxoSmithKline where he managed the legal and communications strategies for several high-profile matters involving the New York Attorney General’s Office, U.S. Department of Justice and U.S. FDA. Before joining the pharmaceutical industry, Doug was associate general counsel for the FDA, where he counseled its commissioner, appeared before the U.S. Congress in key initiatives and led the initial false claims/kickback cases against the pharmaceutical industry.
Doug earned a bachelor’s degree from Dickinson College, Carlisle, Pennsylvania, and his Juris Doctorate from Columbus School of Law at The Catholic University of America, Washington, DC.
“Our people get it. If you’re someone who wants to work hard for families living with rare neurological disorders, someone who believes in finding a path forward for families to get the medicines they so desperately need, then this is the company for you.”
Tina St. Leger is GW’s chief human resources officer, a role she has held since joining the company in July 2019. She has over 20 years of global human resources experience, with particular expertise in organizational and leadership development and the pharmaceutical industry.
As CHRO, Tina is responsible for all human resources functions, including talent acquisition, talent development and management, compensation, benefits and HR business partnership.
Prior to GW, Tina spent 14 years at GlaxoSmithKline, most recently as vice president of human resources for GSK Europe and GSK’s global therapeutic areas. In that role, she led change initiatives across Europe and the U.S. for a division spanning 30 countries and 5,000 employees and built the global oncology team in the U.S. and Europe. Previously, she held HR leadership positions at GSK, including vice president of human resources for the emerging markets region and the branded generics business with 17,000 employees and operations in over 100 countries, and vice president of human resources for ViiV Healthcare—a joint venture company formed between GSK, Pfizer and Shionogi specializing in HIV. Tina had overall global human resources responsibility for ViiV with presence in the U.S., Europe and Asia. Before her tenure at GSK, Tina was the leadership and development head for the UK retailer Marks and Spencer after an earlier career in finance and R&D.
Tina earned a Bachelor of Science in chemistry from the University of St. Andrews, UK.
“We are driven, and have been right from the start, to find a way forward for creating cannabinoid based medicines, to validate the science and follow the gold standard medicines development approach, because the families we serve need them, and we work tirelessly to find a way for them.”
Chris Tovey is GW’s chief operating officer, a role he has held since joining the company in October 2012. He has over 30 years of commercial and operations experience in the pharmaceutical industry.
As COO, Chris is responsible for all international commercial activities beyond the US, manufacturing and supply chain, and information systems and security.
Prior to GW, Chris spent six years at UCB Pharmaceuticals in multiple roles, most recently as vice president of global marketing operations with responsibility for worldwide marketing activities on a product portfolio generating over $2B in annual sales, as well as managing director for Greece and Cyprus, and leader of the Business Unit responsible for the orphan narcotic medication Xyrem for the treatment of narcolepsy. Previously, he spent 18 years at GlaxoSmithKline in senior commercial roles, including director of commercial strategy for Europe distribution, director of the European vaccines therapy area, director of UK commercial development and director of the UK vaccines business. During his tenure at GSK, Chris worked across a wide range of therapeutic areas, including infectious diseases, epilepsy, psychiatry, oncology, diabetes, respiratory and immunology. He started his career in pharmaceutical sales at Beecham Pharmaceuticals.
Chris holds a Bachelor of Science in marine biology from the University of Liverpool, UK.